# Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Canonical URL: https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-presentation-highlighting-silevertinib-phase-2-clinical-trial-results-and-program-update
Ticker: BDTX
Company: Black Diamond Therapeutics
Source: Black Diamond Therapeutics
Published: 2025-12-02 21:01 EST
Original Source URL: https://investors.blackdiamondtherapeutics.com
## Summary

Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host

## Article Body
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host
## Recent Company News
- 2026-05-22 12:00 EST — [Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-confere-9abd2552) — Source: Black Diamond Therapeutics
- 2026-05-21 21:14 EST — [Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations) — Source: Black Diamond Therapeutics
- 2026-05-19 12:00 EST — [Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-to-host-webcast-for-investors-highlighting-updated-results-from-phase-2-trial-of-silevertinib-in-1l-egfrm-nsclc) — Source: Black Diamond Therapeutics
- 2026-05-07 11:30 EST — [Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Black Diamond Therapeutics
- 2026-04-21 14:40 EST — [Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/BDTX/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting) — Source: Black Diamond Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)